מחקר פורץ דרך שנערך במרכז הרפואי "רבין", בית חולים "השרון", מצא כי לטכנולוגיה של חברת MeMed פוטנציאל לסייע בהתאמת הטיפול התרופתי לחולי קורונה (COVID-19)
23 juil. 2020 06h00 HE
|
MeMed
מחקר פורץ דרך שנערך במרכז הרפואי "רבין", בית חולים "השרון", מצא כי לטכנולוגיה של חברת MeMed פוטנציאל לסייע בהתאמת הטיפול התרופתי לחולי קורונה (COVID-19) שימוש בפלטפורמת ה-MeMed Key™, לטובת אבחון מהיר...
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
23 juil. 2020 06h00 HE
|
MeMed
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients Rapid and Continuous Measurement of the Host-Immune Response with...
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
23 juil. 2020 06h00 HE
|
MeMed
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients Rapid and Continuous Measurement of the Host-Immune Response with...
前瞻性研究发现 MeMed 的宿主免疫技术对个体化治疗新冠病毒肺炎重症患者具有潜在效用
23 juil. 2020 06h00 HE
|
MeMed
前瞻性研究发现 MeMed 的宿主免疫技术对个体化治疗新冠病毒肺炎重症患者具有潜在效用 使用 MeMed Key™ 快速连续地测量宿主免疫应答，有助临床医生预测新冠病毒肺炎的严重程度、监测炎症状态及指导治疗决策 以色列海法，2020 年 7 月 23 日——以色列拉宾综合医学中心（贝林松医院和哈沙隆医院）的研究人员与 MeMed 合作发布前瞻性数据，说明宿主免疫生物标志物 IP-10...
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
23 juil. 2020 06h00 HE
|
MeMed
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients Rapid and Continuous Measurement of the Host-Immune Response with...
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform
02 juin 2020 07h00 HE
|
MeMed
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform Cutting-edge instrument platform and a novel host-immune response signature test...
Marchio CE per due tecnologie pionieristiche di MeMed: il test MeMed BV™ e la piattaforma diagnostica MeMed Key™
02 juin 2020 01h00 HE
|
MeMed
Marchio CE per due tecnologie pionieristiche di MeMed: il test MeMed BV™ e la piattaforma diagnostica MeMed Key™ Una piattaforma strumentale all’avanguardia e un nuovo signature test sulla...
MeMed erhält CE-Kennzeichnung für zwei wegweisende Technologien: den MeMed BV™-Test und die MeMed Key™ Point-of-Need-Plattform
02 juin 2020 01h00 HE
|
MeMed
MeMed erhält CE-Kennzeichnung für zwei wegweisende Technologien: den MeMed BV™-Test und die MeMed Key™ Point-of-Need-Plattform Hochmoderne Instrumentenplattform und neuartiger Signaturtest für...
MeMed a obtenu le marquage CE pour deux de ses technologies novatrices : le test MeMed BV™ et la plateforme MeMed Key™
02 juin 2020 01h00 HE
|
MeMed
MeMed a obtenu le marquage CE pour deux de ses technologies novatrices : le test MeMed BV™ et la plateforme MeMed Key™ Plateforme instrumentale de pointe et un test novateur de la signature...
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform
02 juin 2020 01h00 HE
|
MeMed
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform Cutting-edge instrument platform and a novel host-immune response signature test...